Skip to main content
. Author manuscript; available in PMC: 2007 Nov 2.
Published in final edited form as: FASEB J. 2006 May 23;20(9):1498–1500. doi: 10.1096/fj.05-5319fje

Figure 8.

Figure 8

Lovastatin inhibits the access of LPS induced phosphorylated ANXA1 on the cell-surface. FACS analysis (A) and Western blot (B) of ANXA1-S27-PO4 expression after lovastatin treatment (10 μM, 16 h). Cells were pretreated with lovastatin (lova) or lovastatin and mevalonic acid (Mev, 10 μM), lovastatin and FPP (5 μM), lovastatin and GGPP (5 μM), lovastatin, and cholesterol (CH, 200 μM) followed by 5 min of LPS stimulation. Cells were harvested and processed both for FACS (A) or Western blot (B, see Materials and Methods). *P < 0.01 vs. unstimulated cells; #P < 0.025 vs. LPS stimulated cells; +P < 0.025 vs. lovastatin+LPS treated cells (ANOVA and Bonferroni test)